Latest News
Braveheart Bio, Inc.
- Braveheart Bio's (BRVE) Overweight Rating Reaffirmed at Cantor Fitzgerald
- Braveheart Bio (NASDAQ:BRVE) Shares Gap Up - Here's Why
- Braveheart Bio (NASDAQ:BRVE) Stock Price Up 7.9% - Should You Buy?
- Braveheart Bio: In Non-Obstructive HCM, The Therapeutic Window Is The Product (BRVE)
- Braveheart Bio, Inc. (NASDAQ:BRVE) Shares Shorted: Short Interest Up 67.8% in September
- Braveheart Bio (NASDAQ:BRVE) Shares Down 7.6% - Time to Sell?
- Braveheart Bio (NASDAQ:BRVE) Reaches New 52-Week Low - Time to Sell?
- Stifel reiterates Buy on Braveheart Bio stock, $45 target By Investing.com
- Braveheart Bio (NASDAQ:BRVE) Stock Jumps 8.1% - Still a Buy?
- Braveheart Bio (NASDAQ:BRVE) Shares Down 7.3% - Here's What Happened
- Braveheart Bio, Inc. (NASDAQ:BRVE) Shares Shorted: Short Interest Up 76.1% in September
- Braveheart Bio (NASDAQ:BRVE) Sets New 12-Month Low - Should You Sell?
Headlines from the last 30 days, linking to the original publishers. See all market news →